INTRODUCTION

Occupational exposure accounts for 17% of adult-onset asthma. Toluene diisocyanate (TDI) is a commonly used diisocyanate and is known to be a cause of occupational asthma (OA). Subjects with TDI-induced OA (TDI-OA) usually experience progressive declines in lung function and sustained respiratory symptoms even in the absence of additional exposure. Exposure to TDI can occur in workplaces that produce flexible polyurethane foam and other products. Although the incidence of TDI-OA has been declining through protection and regulation policies, use of TDI has not decreased and many workers are still at high risk of TDI-OA. TDI has a low molecular weight and is a highly reactive chemical. Although many efforts to address the pathogenesis of TDI-OA have been made, its nature is heterogeneous in which various immunologic and non-immunologic mechanisms are involved.

Periostin is a secreted, 90-kDa extracellular protein with a structure homologous to adhesion molecule fasciclin I. It has the ability to bind fibronectin, tenascin-c, and collagen and to

Serum Periostin Levels: A Potential Serologic Marker for Toluene Diisocyanate-Induced Occupational Asthma

Ji-Ho Lee¹, Sang-Ha Kim¹, Youngwoo Choi², Hoang Kim Tu Trinh², Eun-Mi Yang², Ga-Young Ban³, Yoo Seob Shin², Young-Min Ye², Kenji Izuhara⁴, and Hae-Sim Park²

¹Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju;
²Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon;
³Department of Pulmonary, Allergy and Critical Care Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea;
⁴Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.

Purpose: Toluene diisocyanate (TDI) is a leading cause of occupational asthma (OA). Periostin is a matricellular protein implicated in type 2 immunity-driven asthma. Its pathogenic role in TDI-OA has not been completely elucidated. The present study was performed to investigate the role of periostin in TDI-OA.

Materials and Methods: Serum periostin levels were measured in subjects with TDI-OA, asymptomatic TDI-exposure controls (AECs), non-occupational asthmatics (NAs), and unexposed normal controls (NCs). To understand the mechanism by which TDI induces periostin production, primary small airway epithelial cells (SAECs) were cultured under stimulation of TDI and neutrophils from asthmatic patients.

Results: Fifty-three subjects with TDI-OA, 71 AECs, 67 NAs, and 83 NCs were enrolled. Serum periostin levels were significantly higher in TDI-OA subjects than in AECs (p=0.001), NAs (p<0.001), and NCs (p<0.001). In TDI-exposed subjects (TDI-OA and AEC), the PC₂₀ methacholine levels were significantly lower in subjects with a higher periostin level than in those with a lower periostin level. TDI exposure did not increase periostin production directly by SAECs; however, periostin production increased significantly after co-culture with TDI and neutrophils, which was suppressed by an antioxidant. In addition, increased release of TGF-β1 was noted from SAECs when exposed to TDI and neutrophils, which was also suppressed by an antioxidant.

Conclusion: These results suggest that an increased periostin level may contribute to the progression of airway inflammation to remodeling in TDI-exposed workers. A high serum periostin level is a potential serologic marker of the phenotype of TDI-OA.

Key Words: Diisocyanate, occupational asthma, periostin, neutrophils, reactive oxygen species
constitute subepithelial fibrosis with other extracellular matrix proteins. Periostin plays an important role in inflammation as a matricellular protein. It has autocrine effects in bronchial epithelial cells and paracrine effects in airway fibroblasts to activate transforming growth factor-β1 (TGF-β1) and type I collagen. Periostin has been implicated in various allergic diseases, such as asthma, chronic rhinosinusitis with nasal polyp, allergic conjunctivitis, and atopic dermatitis. However, the role of periostin in the pathogenesis of TDI-OA has not yet been completely elucidated.

As periostin may be involved in the pathogenic mechanisms of airway inflammation and remodeling in TDI-OA, this study was conducted to compare serum periostin levels among TDI-OA subjects, asymptomatic TDI-exposure controls (AECs), adult non-occupational asthmatics (NAs), and normal controls (NCs) not exposed to TDI and to investigate underlying mechanisms by which periostin is released from airway epithelial cells in TDI-exposed workers.

MATERIALS AND METHODS

Study population
Fifty-three subjects with TDI-OA, 71 AECs, 67 NAs, and 83 NCs were recruited in Ajou University Medical Center (Suwon, South Korea). TDI-OA was defined as the presence of a history of TDI exposure in the workplace and a positive response to TDI provocation test. AECs were subjects with a history of exposure to TDI in the workplace and no symptoms relating due to asthma. NAs were subjects diagnosed with aspirin tolerant and non-severe asthma. NAs or NCs did not have a history of exposure to TDI. Blood samples were collected 1 week after discontinuation of all asthma medications, including inhaled/systemic corticosteroids and leukotriene receptor antagonists, and were stored at -20°C until used. Blood sampling was performed at the initial visit of each patient at which time most of the study subjects had been exposed to TDI. Atopic status was determined by results of skin prick test with common inhalant allergens (Bencard, Bradford, UK), wherein atopy was considered present if the test elicited positive reactions to at least one allergen. Total IgE was measured using the ImmunoCAP system (Thermo Fisher Scientific, Waltham, MA, USA). Informed consent was obtained from all patients. This study was approved by the Ethical Review Board of Ajou University Hospital (AJIRB-GEN-SMP-13-108).

Provocation test with methacholine and TDI
Methacholine bronchial provocation test was conducted according to generally accepted guidelines. Doubled doses of methacholine (0.075 mg/mL to 25 mg/mL) were inhaled by the dosimeter method at 5 minute intervals until a fall in forced expiratory volume in 1 s (FEV₁) 20% or more. PC_{20} level, a concentration of methacholine in which FEV₁ decrease by 20%, was calculated by interpolation from the dose-response curve between methacholine and FEV₁. TDI provocation test was performed following a previously described method. Subjects were exposed to TDI (2,4 form:2,6 form=80:20; Sigma-Aldrich, St Louis, MO, USA) for 5 to 45 minutes through tidal breathing in a closed room until respiratory symptoms occurred. FEV₁ was measured before and 5 hours after the TDI exposure. If a fall in FEV₁ was 20% or more, the results of TDI provocation test was considered positive.

TDI-HSA conjugate
TDI-human serum albumin (TDI-HSA) conjugate was kindly provided by Dr. Justin M. Hettick (National Institute for Occupational Safety and Health, Morgantown, WV, USA), and 2,6-TDI was conjugated by HSA at different ratios and at a concentration of 0.5 mg/mL. Three different ratio (TDI:HSA), 40:1, 10:1 and 5:1, were provided. Conjugation between TDI and HSA, cross-linking, and reactivity were demonstrated. Among them, TDI-conjugated HSA at 40:1 was more reactive than the others in enzyme-linked immunosorbent assay (ELISA). Therefore, 40:1 TDI-HSA conjugate was used in this study.

Measurement of periostin and other cytokines
Periostin, interleukin-8 (IL-8), and TGF-β1 levels in serum samples and cell culture supernatants were measured by commercial ELISA kits (Shino-Test Corporation, Tokyo, Japan; Endogen, Woburn, MA, USA; and R&D Systems, Minneapolis, MN, USA, respectively), following the manufacturers’ instructions. The serum levels of myeloperoxidase (MPO) and IL-1β in cell supernatants were also measured by commercial ELISA kits (Biocheck Inc, Foster City, CA, USA and R&D Systems, respectively).

Measurement of intracellular reactive oxygen species
2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) was purchased from Molecular Probes (Eugene, OR, USA) and was used as a fluorescent probe to detect the extent of reactive oxygen species (ROS) activation. Isolated neutrophils from asthmatic patients at a concentration of 1×10^6 cells/mL were treated with phosphate buffered saline (PBS), TDI-HSA conjugate, and TDI-HSA conjugate with N-Acetyl-L-cysteine (NAC) (Sigma-Aldrich) for 24 hours and incubated with 50 μM H2DCF-DA for 30 minutes at 37°C. They were analyzed using a FACS Canto II flow cytometer (BD Biosciences, San Jose, CA, USA).

Isolation of peripheral blood neutrophils
Venous blood was collected from adult asthmatics in BD Vacutainer tubes containing acid citrate dextrose solution (BD Biosciences) and was processed immediately after collection following a previously described method. Blood was layered on Lymphoprep solution (Axis-Shield, Oslo, Norway), which was then centrifuged at 2000 rpm and 20°C for 25 minutes. The bottom red layer was mixed with Hank’s balanced salt solution (HBSS) buf-
Human airway epithelial cell culture and treatment

Three human airway epithelial cells (HAECs), including A549 cells, BEAS-2B cells, and primary small airway epithelial cells (SAECs), were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and were cultured following previously reported methods. A549 and BEAS-2B cells were cultured in RPMI-1640 medium with 10% heat-inactivated FBS, penicillin (100 IU/mL), and streptomycin (50 μg/mL). SAECs were cultured in Airway Epithelial Cell Basal Medium (ATCC), supplemented with HSA 500 mg/mL, linoleic acid 0.6 mM, lecithin 0.6 mg/mL, L-glutamine 6 mM, extract P 0.4%, epinephrine 1.0 mM, transferrin 5 mg/mL, triiodothyronine 10 nM, hydrocortisone 5 mg/mL, epidermal growth factors 5 μg/mL, and insulin 5 mg/mL. Cells were maintained at 37°C with 5% CO₂ in humidified air.

HAECs (1×10⁶ cells/mL) were treated with 10 μL of 1 μg/mL TDI-HSA conjugate and/or 10 μL of 1 mM NAC for 24 hours. Isolated neutrophils at 0.5×10⁶ cells/mL, an optimal count in previous experiments, were co-cultured with HAECs in trans-wells to interfere with direct contact between neutrophils and HAECs. Supernatants were collected and frozen at -80°C until ready for use.

Statistical analysis

Subject characteristics were analyzed using Student’s t test or the Mann-Whitney U test for continuous variables and the chi-square test or Fisher’s exact test for categorical variables. Analyses among three or more groups were performed using one-way ANOVA with Bonferroni post hoc test. Correlations between periostin and other cytokines were analyzed by applying Spearman’s rank coefficient (r). Receiver operating curves (ROCs) were used to determine a cutoff value for serum periostin levels that differentiated TDI-OA and TDI-exposed subjects from healthy controls. Clinical and inflammatory parameters were compared by a generalized linear model between subjects with a higher periostin level and those with a lower periostin level. All statistical analyses were performed with SPSS version 23.0 (IBM Corp., Armonk, NY, USA). A p value of less than 0.05 was considered statistically significant.

RESULTS

Characteristics of the study subjects

The mean ages of the subjects with TDI-OA, AECs, NAs, and NCs were 42.8±9.6, 40.0±9.0, 46.5±12.5, and 39.1±13.5 years, respectively (p<0.001) (Table 1). The proportions of males among subjects with TDI-OA, AECs, NAs, and NCs were 64.2, 69.0, 44.8, and 53.6%, respectively (p=0.001). The proportion of ever smokers among AECs (59.4%) was significantly higher than those among TDI-OA, NAs, and NCs (25.6, 14.3, and 8.4%, respectively, p<0.001). The duration of TDI exposure was significantly shorter in subjects with TDI-OA than in AECs (6.9±4.6 vs. 13.3±8.6 years, p=0.015). The serum total IgE levels, FEV₁ (%), and PC₂₀ levels were comparable among the groups.

Elevated levels of serum periostin in TDI-OA

The mean serum periostin level was 127.6±79.5 ng/mL in subjects with TDI-OA, which was significantly higher than that in TDI-OA plus AECs (59.4%) was significantly higher than those among TDI-OA, NAs, and NCs (25.6, 14.3, and 8.4%, respectively, p<0.001). The duration of TDI exposure was significantly shorter in subjects with TDI-OA than in AECs (6.9±4.6 vs. 13.3±8.6 years, p=0.015). The serum total IgE levels, FEV₁ (%), and PC₂₀ levels were comparable among the groups.

Comparison of clinical and immunologic parameters in subjects with TDI-OA plus AECs

Clinical and immunologic parameters in subjects with TDI-OA plus AECs were analyzed according to a cutoff periostin value

### Table 1. Clinical Characteristics of the Study Subjects

|                      | TDI-OA (n=53) | AEC (n=71) | NA (n=67) | NC (n=83) | p value |
|----------------------|--------------|------------|-----------|-----------|---------|
| Age (yr)             | 42.8±9.6     | 40.0±9.0   | 46.5±12.5 | 39.1±13.5 | <0.001  |
| Sex (male)           | 34 (64.2)    | 49 (69.0)  | 30 (44.8) | 45 (63.6) | 0.001   |
| Ever smoker          | 11/43 (25.6) | 41/69 (59.4)| 6/42 (14.3)| 7/83 (8.4) | <0.001  |
| Atopy                | 21/44 (47.7) | -          | 26/65 (40.0)| 13/64 (20.3)| 0.051   |
| TDI exposure duration (yr) | 6.9±4.6     | 13.3±8.6   | -         | -         | 0.015   |
| Asthma duration (yr) | 7.1±4.2      | -          | 5.4±6.5   | -         | 0.224   |
| Serum total IgE (IU/L) | 363.8±504.4 | 96.0±87.0 | 291.4±361.5| 151.5±224.2| 0.544   |
| FEV₁ (% predicted)  | 87.2±21.6    | 96.6±20.8 | 85.7±23.0 | -         | 0.796   |
| PC₂₀ (mg/mL)         | 5.8±9.2      | 7.4±9.5   | 10.6±12.6 | -         | 0.436   |

TDI, toluene diisocyanate; TDI-OA, TDI-induced occupational asthma; AEC, asymptomatic TDI-exposure control; NA, non-occupational asthma; NC, normal healthy control; FEV₁, forced expiratory volume in 1 s; PC₂₀, concentration of methacholine required to decrease a 20% in FEV₁.

Data are presented as the mean±SD or n (%).

https://doi.org/10.3349/ymj.2018.59.10.1214
Table 2. Comparison of Clinical and Immunologic Parameters in Terms of Serum Periostin Level in TDI-Exposed Subjects

| Serum periostin level | High (n=37) | Low (n=87) | p value* |
|-----------------------|-------------|------------|----------|
| Age [yr]              | 41.9±8.9    | 40.9±9.5   | 0.594    |
| Sex [male]            | 17 (45.9)   | 66 (75.9)  | 0.002    |
| Ever smoker           | 7/31 (22.6) | 45/81 (55.6)| 0.003   |
| Atopy                 | 10/17 (58.8)| 11/28 (39.3)| 0.233   |
| TDI exposure duration [yr] | 6.1±5.0   | 10.1±7.1 | 0.100    |
| Asthma duration [yr]  | 7.7±3.6     | 6.6±4.7   | 0.521    |
| Serum total IgE [IU/mL] | 359.6±405.4| 251.8±458.1| 0.356   |
| FEV1 (% predicted)    | 87.1±18.5   | 89.1±23.1 | 0.782    |
| PC20 [mg/mL]          | 1.9±2.5     | 8.0±10.5  | 0.028    |
| IL-8 [pg/mL]          | 53.7±78.5   | 43.7±49.2 | 0.405    |
| MPO [ng/mL]           | 169.7±130.3 | 162.0±179.5| 0.540   |
| TGF-β1 [ng/mL]        | 44.3±16.4   | 48.6±46.6 | 0.956    |

TDI, toluene diisocyanate; FEV1, forced expiratory volume in 1 s; PC20, concentration of methacholine required to decrease a 20% in FEV1; MPO, myeloperoxidase.

Data are presented as the mean±SD or n (%).

*p value was obtained with an adjustment for age, sex and smoking history.

ROS production by neutrophils in response to TDI-HSA conjugate

In asthmatic patients, ROS production by neutrophils in response to TDI-HSA conjugate was measured by mean fluorescence intensity of fluorescent probe H2DCFDA using flow cytometry. ROS production by neutrophils was significantly increased after treatment with TDI-HSA conjugate, compared to treatment with PBS (Fig. 2A). However, NAC suppressed ROS production to a similar extent as that with PBS. No significant effect of TDI-HSA conjugate on IL-1β production by neutrophils was noted (Fig. 2B).

Effect of TDI and neutrophils on immune response in HAECs

Three kinds of HAECs were co-cultured with TDI-HSA conjugate. Their viability was evaluated by CCK8 assay. No significant change in viability was detected (Supplementary Fig. 2A, only online). In addition, the release of IL-8 and IL-6 from HAECs was not affected by treatment with TDI-HSA conjugate (Supplementary Fig. 2B and C, only online).

IL-8 release was significantly increased after co-culture with neutrophils in BEAS-2B cells and SAECs in response to TDI-HSA conjugate (Fig. 3A). Periostin was not detected in cell supernatants from A549 and BEAS-2B cells regardless of neutrophil co-culture and TDI-HSA treatment. In SAECs, periostin was released at a low level without any treatment. Although TDI-HSA conjugate alone did not increase periostin, periostin increased significantly when co-cultured with neutrophils, which was further increased by treatment with TDI-HSA conjugate. NAC decreased periostin to a similar extent as that in negative controls (Fig. 3B). In addition, co-culture with neutrophils significantly increased TGF-β1 from SAECs, which was further...
increased by treatment with TDI-HSA. However, NAC remarkably decreased TGF-β1 (Fig. 3C). In addition, within culture supernatants from SAECs, periostin levels were significantly correlated with IL-8 levels (r=0.941, p<0.001) (Fig. 3D) and TGF-β1 levels were significantly correlated with periostin (r=0.830, p<0.001) (Fig. 3E) and IL-8 levels (r=0.829, p<0.001) (Fig. 3F).

**DISCUSSION**

In the present study, we found that serum periostin levels were significantly higher in TDI-OA than in AECs, NAs, and NCs. PC_{20} methacholine levels were significantly lower in subjects with a higher periostin level than in those with a lower periostin level. TDI exposure did not increase periostin production directly by airway epithelial cells. However, periostin production by airway epithelial cells increased significantly after coculture with neutrophils, which were suppressed by an antioxidant. In addition, TGF-β1 production by airway epithelial cells increased when exposed to TDI and neutrophils, which was also suppressed by an antioxidant. This is the first study to suggest that high periostin levels induced by airway epithelial cells may contribute to the progression of airway inflammation leading to airway remodeling in subjects with TDI-OA.

Serum periostin has been regarded as a biomarker for bronchial asthma, especially in T-helper 2 (Th2)-driven asthma.
phenotype. IL-13 is a central cytokine for the development of type 2 immune response. The periostin gene POSTN is highly expressed by IL-13 in bronchial epithelial cells. In immunohistochemical analysis of bronchial biopsy specimens from asthmatic patients, periostin was deposited on the thickened basement membrane, indicating that periostin plays a pathogenic role in bronchial asthma as a constituent of subepithelial fibrosis. Gene expression studies with airway epithelial brushings and sputum cells have shown that periostin is also found to be highly expressed in the Th2-high subtype, compared to the Th2-low subtype. In this regard, biologic agents targeting type 2 immunity, such as anti-IL-13 antibody (lebrikizumab) and anti-IgE antibody (omalizumab), may have a significant therapeutic effect in subjects with higher periostin levels, compared to those with lower levels. However, despite accumulating evidence of periostin involvement in Th2 phenotype of bronchial asthma, there is a lack of research on whether periostin is associated with other phenotypes of asthma.

In the present study, the mean serum level of periostin in subjects with TDI-OA was 127.6 ng/mL, which is higher than levels in other study subjects with non-occupational asthma (ranging from 76.5 ng/mL to 92.8 ng/mL). These findings suggest that another mechanism other than type 2 immunity may contribute to the production of periostin by airway epithelial cells. Various immunologic and non-immunologic mechanisms have been shown to be involved in the pathogenesis of TDI-OA. Among them, ROS production in response to TDI exposure in the workplace has been found to play a crucial role in the development of airway inflammation. In addition, exposure to TDI rapidly decreases glutathione levels, and other antioxidants, such as thioredoxin, ferritin, and heme oxygenase-1, are also affected in TDI-OA. As a result, ROS can initiate inflammatory responses through activation of nuclear factor-kappaB and hypoxia-inducible factor, which induce inflammatory cascades in airway epithelial cells. Moreover, production of IL-8, a potent chemotactic factor for neutrophils, is increased in airway epithelial cells in response to TDI. Activated neutrophils are the most intense producers of ROS. In the present study, TDI increased ROS production by neutrophils, and neutrophils increased release of periostin from epithelial cells, which was further increased by TDI and suppressed by NAC, an antioxidant. Therefore, increased ROS production by neutrophils can be considered another contributing factor to the release of periostin from airway epithelial cells in pathogenic mechanisms of airway inflammation of TDI-OA.

TGF-β1 is considered a key mediator of airway remodeling including subepithelial fibrosis. Airway remodeling is closely linked with the degree of airway hyperresponsiveness. Activated airway epithelial cells release a large amount of periostin, which in turn activates TGF-β1 production by epithelial cells through an autocrine effect mediated by matrix metalloproteinase (MMP)-9. MMP-9 was also found to be increased in induced sputum from subjects with TDI-OA after the TDI provocation test. In the present study, subjects with a higher periostin level showed more severe airway hyperresponsiveness to methacholine than those with a lower periostin level. Additionally, periostin release from SAECs was well correlated with that of TGF-β1. Although whether TGF-β1 contributes to airway remodeling was not confirmed in this study, these experimental results indicate ROS-induced periostin released from airway epithelial cells may interact with TGF-β1.

There is no direct evidence to demonstrate that periostin is associated with neutrophilic inflammation. However, recent studies on idiopathic pulmonary fibrosis (IPF) suggest that periostin is a potential mediator involved in airway neutrophilic inflammation. Serum periostin levels were found to be significantly higher in patients with IPF than in those with other subtypes of interstitial lung disease, and lung function was inversely correlated with periostin levels. In a mouse model of bleomycin-induced IPF, pulmonary fibrosis, recruitment of neutrophils and chemokines for neutrophils were significantly decreased in periostin-deficient mice, suggesting that periostin may be associated with neutrophil activation in lung tissue. TDI-OA has been regarded as a phenotype of severe asthma with airway remodeling and is characterized by neutrophilic inflammation. In the present study, neutrophils increased periostin release from airway epithelial cells, which was further increased after co-exposure to TDI and neutrophils. These findings suggest that TDI exposure, along with neutrophilic inflammation, as well as Th2 immune responses, could increase periostin production by airway epithelial cells, thereby exacerbating the progression of airway inflammation and remodeling, resulting in a decline in lung function in subjects with TDI-OA.

Several studies have outlined the roles of epithelial cell-derived molecules (folliculin, clusterin, and progranulin), which are mediated by ROS injury, in the pathogenesis of TDI-OA. They can be induced from airway epithelial cells under short-term exposure to TDI with neutrophils in in vitro systems, while clusterin/progranulin may be depleted with chronic exposure. Therefore, lower serum levels of clusterin/progranulin were noted in TDI-OA patients, which may enhance ROS injury. The present study suggests that periostin is an additional epithelial cell-derived molecule in response to TDI/neutrophils-induced ROS. Future research needs to study interactions among these mediators in the pathogenesis of TDI-OA.

Periostin has been suggested as a potential biomarker for chronic upper and lower airway diseases, including Th2-asthma. Periostin is easily secreted from inflamed tissues into body fluids, including blood and sputum. Serum periostin levels can appropriately reflect inflamed tissue and can be more accurately detected, compared to other biomarkers. In the diagnosis of TDI-OA, there have been no studies to dem-
onstrate and validate a reliable in vitro test to differentiate TDI-OA subjects from those with the other types of non-occupational asthma or AEC and NC individuals. In this regard, the present study suggests that a serum periostin level higher than a specific cut-off value may be a potential serum biomarker for predicting the phenotype of TDI-OA with high diagnostic accuracy, although more prospective studies in other cohorts of TDI-exposed workers will be needed to validate this hypothesis. Also, further studies will be needed to explore the exact mechanism by which periostin induces TGF-β1 production in the airway mucosa of subjects with TDI-OA and whether a high periostin level can be used to predict progression of airway remodeling in subjects with TDI-OA.

There are several limitations in this study. First, we collected neutrophils isolated from non-occupational asthmatic patients, which may not be able to reflect exact functional status of neutrophils derived from subjects with TDI-OA. Secondly, we did not demonstrate that ROS directly mediated production of periostin and TGF-β1 by SAEC. It is possible that other mediators released from TDI-HSA activated neutrophils promote production of them. Thirdly, the long-term prognosis of subjects with a higher periostin level, especially AECs, was not evaluated, since this study was conducted as a cross-sectional study. A long-term patient cohort is warranted.

In conclusion, the results of this study suggest that increased levels of periostin may contribute to progression of airway inflammation/remodeling in the airway mucosa of subjects with TDI-OA, leading to poor outcomes. Serum levels of periostin could be a potential serologic marker for representing the phenotypes of TDI-OA. Further prospective studies are needed to monitor the long-term prognosis of subjects with TDI-OA stratified by serum periostin levels.

ACKNOWLEDGEMENTS

This research was supported by a grant (HI14C2628) from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea and a grant from the Korean Society of Occupational Asthma and Lung Diseases.

ORCID

Hae-Sim Park https://orcid.org/0000-0003-2614-0303

REFERENCES

1. Torén K, Blanc PD. Asthma caused by occupational exposures is common - a systematic analysis of estimates of the population-attributable fraction. BMC Pulm Med 2009;9:7.
2. Cassidy LD, Doney B, Wang ML, Kurth L, Conner PR, Collins JJ, et al. Medical monitoring for occupational asthma among toluene diisocyanate production workers in the United States. J Occup Environ Med 2017;59 Suppl 12:S13-21.
3. Rtiegger M, Droste D, Hofmann M, Jost M, Miedinger D. Diisocyanate-induced asthma in Switzerland: long-term course and patients’ self-assessment after a 12-year follow-up. J Occup Med Toxicol 2014;9:21.
4. Collins JJ, Anteau S, Conner PR, Cassidy LD, Doney B, Wang ML, et al. Incidence of occupational asthma and exposure to toluene diisocyanate in the United States toluene diisocyanate production industry. J Occup Environ Med 2017;59 Suppl 12:S22-7.
5. Diller WF. Frequency and trends of occupational asthma due to toluene diisocyanate: a critical review. Appl Occup Environ Hyg 2002;17:872-7.
6. Vandenplas O. Occupational asthma: etiologies and risk factors. Allergy Asthma Immunol Res 2011;3:157-67.
7. Parulekar AD, Atik MA, Hanania NA. Periostin, a novel biomarker of TH2-driven asthma. Curr Opin Pulm Med 2014;20:60-5.
8. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Sjoji S, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006;118:98-104.
9. Ferrando M, Bagnasco D, Varricchi G, Bernardi S, Bragantini A, Passalacqua G, et al. Personalized medicine in allergy. Allergy Asthma Immunol Res 2017;9:15-24.
10. Liu A, Zheng H, Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol 2014;37:150-6.
11. Wardzyńska A, Makowska JS, Pawelczyk M, Piechota-Poláčiková A, Kurowski M, Kowalski ML. Periostin in exhaled breath condensate and in serum of asthmatic patients: relationship to upper and lower airway disease. Allergy Asthma Immunol Res 2017;9:126-32.
12. Kim DW, Cho SH. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. Allergy Asthma Immunol Res 2017;9:299-306.
13. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000;161:309-29.
14. Park HS, Kim HY, Nahm DH, Son JW, Kim YY. Specific IgG, but not specific IgE, antibodies to toluene diisocyanate-human serum albumin conjugate are associated with toluene diisocyanate bronchoprovocation test results. J Allergy Clin Immunol 1999;104(4 Pt 1):847-51.
15. Mihke M, Hettick JM, Chipinda I, Law BF, Bledsoe TA, Lemons AR, et al. Characterization and comparative analysis of 2,4-toluene diisocyanate and 1,6-hexamethylenediisocyanate haptenated human serum albumin and hemoglobin. J Immunol Methods 2016;431:38-44.
16. Pham DL, Ban GY, Kim SH, Shin YS, Ye YM, Chwae YJ, et al. Neutrophil autophagy and extracellular DNA traps contribute to airway inflammation in severe asthma. Clin Exp Allergy 2017;47:57-70.
17. Ban GY, Pham DL, Trinh TH, Lee SI, Suh DH, Yang EM, et al. Autophagy mechanisms in sputum and peripheral blood cells of patients with severe asthma: a new therapeutic target. Clin Exp Allergy 2016;46:48-59.
18. Izuhara K, Matsumoto H, Ohita S, Ono J, Arima K, Ogawa M. Recent developments regarding periostin in bronchial asthma. Allergol Int 2015;64 Suppl:S3-10.
19. Izuhara K, Ohita S, Ono J. Using periostin as a biomarker in the treatment of asthma. Allergy Asthma Immunol Res 2016;8:491-8.
20. Yuzawa N, Davies DE, Akaiwa M, Matsui K, Hamasaki Y, Sumiyoshi Y, et al. Analysis of novel disease-related genes in bronchial asthma. Cytokine 2002;19:287-96.
21. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-95.
22. Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Fahy JV. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol 2014;133:388-94.
23. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98.
24. Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013;187:804-11.
25. Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguichi T, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013;132:305-12.
26. Kim MA, Izuhara K, Ohta S, Ono J, Yoon MK, Ban GY, et al. Association of serum periostin with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2014;113:314-20.
27. Shin YS, Kim MA, Pham LD, Park HS. Cells and mediators in diisocyanate-induced occupational asthma. Curr Opin Allergy Clin Immunol 2013;13:125-31.
28. Lange RW, Day BW, Lemus R, Tuyrin VA, Kagan VE, Karol MH. Intracellular S-glutathionyl adducts in murine lung and human bronchoepithelial cells after exposure to diisocyanatotoluene. Chem Res Toxicol 1999;12:931-6.
29. Muti AD, Pârvu AE, Muti LA, Moldovan R, Murescu A. Vitamin E effect in a rat model of toluene diisocyanate-induced asthma. Clujul Med 2016;89:499-505.
30. Park HS, Kim SR, Lee YC. Impact of oxidative stress on lung diseases. Respiratory 2009;14:27-38.
31. Qu J, Li Y, Zhong W, Gao P, Hu C. Recent developments in the role of reactive oxygen species in allergic asthma. J Thorac Dis 2017;9: E62-43.
32. Lee YM, Kim HA, Park HS, Lee SK, Nahm DH. Exposure to toluene diisocyanate (TDI) induces IL-8 production from bronchial epithelial cells: effect of pro-inflammatory cytokines. J Korean Med Sci 2003;18:809-12.
33. Winterbourn CC, Kettle AJ, Hampton MB. Reactive oxygen species and neutrophil function. Annu Rev Biochem 2016;85:765-92.
34. Ojiaku CA, Yoo EJ, Panettieri RA Jr. Transforming growth factor β1 function in airway remodeling and hyperresponsiveness. The missing link? Am J Respir Cell Mol Biol 2017;56:432-42.
35. Gabehart KE, Royce SG, Maselli DJ, Miyasato SK, Davis EC, Tang ML, et al. Airway hyperresponsiveness is associated with airway remodeling but not inflammation in aging Cav1-/- mice. Respir Res 2013;14:110.